Skip to main content
IFF logo

IFF · International Flavors & Fragrances Inc

Track IFF — free
$84.28 +0.89 (+1.07%) At close · Aug 21
Market Cap
$21.47B
Shares
255.15M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$84.28 Open$84.10 Day$83.83–85.21 52W close$59.55–88.07 Avg vol 30d1.6M Short int16.4M · 6.4% float · 9.8d Short vol74% Last earningsAug 5, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 4

Up next

Next earnings call
Nov 4, 2026 Est · unconfirmed · in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed Aug 4, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Buy Momentum Strong Sentiment Neutral Fundamentals Fair Quant / Vol Moderate
      Market backdrop VIX 15.1 · calm Equity put/call 0.58
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +15%
      above
      Price vs 50-day avg +6%
      above
      RSI (14) 58
      neutral
      MACD trend Negative
      52-week position 87%
      near high
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Strong
      1-month return +11%
      trailing
      6-month return +4%
      trailing
      YTD return +25%
      this year
      Relative strength −7%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $79 › 200d $74 — 50d above 200d
      Institutional flow Accumulating
      +7% holders QoQ · +115 funds added
      Insider flow Accumulating
      Net +$19.0M over 90 days · 75% sells
      Short interest Rising
      6.43% of float · ▲ +9.2% MoM · 9.8 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      752 holders — mid 3-yr range
      Squeeze score 73
      high risk · 0–100
      Fundamentals
      Fair
      Revenue growth −5%
      Y/Y
      Gross margin 36%
      expanding
      EPS growth −236%
      Y/Y
      Free cash flow $256.0M
      Valuation P/E 76.5
      rich
      Buyback $400.0M
      remaining
      Balance sheet $5.4B
      net debt
      Quant / Vol
      risk profile
      Moderate
      Volatility 36%
      annualized · 1-yr
      Max drawdown −20%
      past year
      ATR 2.9%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 4 of last 4
      Latest guidance · from the 8-K filed Aug 4, 2026
      full year 2026
      Sales Initiated $7.4B – $7.6B
      prior FY $10.89B midpoint −31.1% Y/Y
      Adjusted operating EBITDA Non-GAAP Initiated $1.53B – $1.6B
      2026
      Sales growth impact of foreign exchange 1%
      Adjusted operating EBITDA growth impact of foreign exchange Non-GAAP 2%
      second half of 2026
      Accelerated share repurchase Initiated $500M
      Prior guidance period ended · from the 8-K filed Nov 4, 2025
      Sales · full year 2025 $10.6B – $10.9B
      Adjusted operating EBITDA · full year 2025 $2B – $2.15B
      Comparable currency neutral adjusted operating EBITDA growth · full year 2025 5% – 10%
      Guided vs delivered · last 4 settled
      Sales full year 2025
      guided $10.6B – $10.9B
      $10.89B In line
      Sales full year 2024
      guided $10.8B – $11.1B
      $11.48B Beat +4.9%
      Sales first quarter
      guided $2.7B – $2.8B
      $2.9B Beat +5.4%
      Full year revenue full year 2023
      guided $11.3B – $11.6B
      $11.48B In line

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 3 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +15% Bullish
      Price vs 50-day avg
      +6% Bullish
      RSI (14)
      58 Neutral
      MACD trend
      Negative Bearish
      52-week position
      87% Bullish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $79 › 200d $74 — 50d above 200d
      Institutional flow Accumulating
      +7% holders QoQ · +115 funds added
      Insider flow Accumulating
      Net +$19.0M over 90 days · 75% sells
      Short interest Rising
      6.43% of float · ▲ +9.2% MoM · 9.8 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      752 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $60 Now $84 · 87% Range high $88
      vs 200-day avg +15% vs 50-day avg +6%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Adjusted (Non-GAAP) EPS ex. Amortization non-GAAP $1.74 Six Months Ended June 30, 2026
      Adjusted Operating EBITDA from Continuing Operations non-GAAP $841M Six Months Ended June 30, 2026
      Adjusted Operating EBITDA from Discontinued Operations non-GAAP $275M Six Months Ended June 30, 2026
      Consolidated Adjusted Operating EBITDA Margin non-GAAP 20.9% Three Months Ended June 30, 2026
      Consolidated Segment Adjusted Operating EBITDA Margin non-GAAP 20.6% Three Months Ended June 30, 2026
      Credit Adjusted EBITDA non-GAAP $2.06B Twelve Months Ended June 30, 2026
      GAAP → non-GAAP reconciliation
      GAAP Net income $254M
      +$187M Interest expense
      +$98M Income taxes
      +$948M Depreciation and amortization
      +$341M Specified items
      +$228M Non-cash items
      = Credit Adjusted EBITDA $2.06B
      Free cash flow non-GAAP $378M First Six Months 2026
      Health & Biosciences Segment Adjusted Operating EBITDA non-GAAP $277M Six Months Ended June 30, 2026
      Health & Biosciences Segment Adjusted Operating EBITDA Margin non-GAAP 24.4% Six Months Ended June 30, 2026
      Scent Segment Adjusted Operating EBITDA non-GAAP $258M Six Months Ended June 30, 2026
      Scent Segment Adjusted Operating EBITDA Margin non-GAAP 20.3% Six Months Ended June 30, 2026
      Segment Adjusted Operating EBITDA non-GAAP $803M Six Months Ended June 30, 2026
      Taste Segment Adjusted Operating EBITDA non-GAAP $268M Six Months Ended June 30, 2026
      Total IFF Adjusted Operating EBITDA Inclusive of Discontinued Operations non-GAAP $1.12B Six Months Ended June 30, 2026
      Net debt to credit-adjusted EBITDA non-GAAP 2.5 first quarter 2026
      Adjusted operating EBITDA non-GAAP $2.09B the full year

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Specialty Chemicals — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      IFF
      International Flavors & Fragrances Inc
      this stock
      $21.47B +25.1% -5.2% 76.5 6.4%
      LIN
      Linde PLC
      $224.91B +14.3% +3.0% 31.5 1.2%
      AIQUF
      L Air Liquide SA /Fi
      $123.27B +4.3% 0.0%
      SHW
      Sherwin Williams Co
      $84.14B +7.0% +2.1% 32.0 2.6%
      ECL
      Ecolab Inc.
      $78.91B +7.3% +2.2% 37.8 1.1%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      752
      % held
      106.9%
      Net QoQ
      +14.8M sh
      Top holder
      Dodge & Cox
      Held Float
      View
      Held by Funds
      Fund positions
      657
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      16.4M
      Days to cover
      9.8d
      Change
      +1.4M sh
      View
      Short Volume
      Short vol %
      74%
      As of
      Aug 21, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      205
      Value
      $16.3K
      As of
      Jul 30, 2026
      View
      Off-Exchange
      Off-exchange %
      39.7%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net buying
      Net (90d)
      +$19.0M
      Buyers / Sellers
      1 / 3
      Buyers Sellers
      View
      Congressional Trades Buy
      Member
      Gilbert Cisneros
      Amount
      $1.0K–$15.0K
      Traded
      Nov 18, 2025
      View
      Financials
      Financials
      Revenue (FY)
      $10.9B
      Net income (FY)
      $339.8M
      EPS diluted
      $-1.41
      View
      Buybacks
      Authorized · 3 programs
      $5.0B
      Remaining
      $400.0M
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 4, 2026
      This year
      12
      View
      Proposed Sales
      Value
      $475.7K
      Shares
      5.7K
      Filed
      Aug 17, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 5, 2026
      View
      Investor Relations
      Upcoming events
      2
      View

      Performance

      5D 20D 120D MTD YTD
      IFF +0.1% +11.0% +4.4% +6.4% +25.1%
      SPY -1.4% +3.6% +11.6% +2.5% +12.3%
      vs SPY +1.5% +7.4% -7.2% +3.9% +12.8%

      Capital returns

      Latest dividend
      $0.40 / share · ex Jun 18, 2026
      Declared · upcoming
      $0.40 / share · ex Sep 18, 2026
      Cut 50.6%
      Paid (TTM)
      $1.60 / share · 4 payouts
      Dividend yield (TTM, derived)
      1.90%
      Buyback programs · 3 active · as of Aug 4, 2026
      Authorized (total)
      $5.00B
      Spent (derived)
      $4.60B
      Remaining
      $400.00M
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 51253 CUSIP 459506101 13F (30d) 650 filings 621 filers Visit website Investor relations